Latest Olaparib Stories
More women with high-grade serous ovarian cancer could benefit from drug, according to Maurie Markman, M.D. Plainsboro, NJ (PRWEB) April 20, 2015 The
PHILADELPHIA, April 20, 2015 /PRNewswire-USNewswire/ -- Stand Up To Cancer (SU2C), Ovarian Cancer Research Fund (OCRF), Ovarian Cancer National Alliance (OCNA), and National Ovarian Cancer Coalition
LONDON, April 8, 2015 /PRNewswire/ -- SummaryGBI Research, has released the pharma report -"Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline
Marketresearchreports.biz has announced the addition of the “Ovarian Cancer Therapeutics In Asia-Pacific Markets To 2020: Off Patent Chemo Regimens To Retain Dominance Despite New Launches”
DALLAS, January 22, 2015 /PRNewswire/ -- RnRMarketResearch.com adds Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance
WILMINGTON, Del., Dec. 19, 2014 /PRNewswire/ -- AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved LYNPARZA(TM) (olaparib) capsules.
RnRMarketResearch.com adds “Market Research Report on Global and Chinese Olaparib (CAS 763113-22-0) Industry, 2009-2019” Latest Report to its store. Dallas,
Sales of Breast Cancer Therapies are Expected to Almost Double Through 2023, Fueled by Growth in Several Distinct Market Segments, According to Findings from Decision Resources Group BURLINGTON,
LONDON, July 2, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
- An armed gangster.